Nesiritide for Ventilated Congestive Heart Failure

NCT04455477 — Unknown, 30 participants, Shanghai Zhongshan Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Hemodynamic Effects of Nesiritide on Congestive Heart Failure Patients Receiving Mechanical Ventilation: A Prospective Observational Study

Registry	NCT04455477, acronym HENCHF
Status	Unknown
Study type	Observational
Enrollment	30 (Estimated)
Sponsor	Shanghai Zhongshan Hospital (Other)
Conditions	Congestive Heart Failure, Mechanical Ventilation, Using Nesiritide, Venous Return, Cardiac Function
Interventions	Nesiritide (Drug)
Dates	start 2020-05-14, primary completion 2021-12-31 (estimated), completion 2021-12-31 (estimated), first posted 2020-07-02, last updated 2020-07-02
Locations	1 site in China

-Summary

The congestive heart failure is a common disease among patients who receive cardiac surgery and may lead to prolonged ventilation support. Nesiritide was a potential therapy for congestive heart failure. This study aimed to compare the Nesiritide induced hemodynamical status changes among congestive heart failure patients with invasive ventilation support.

Expand all sections · Collapse all

+Arms and interventions

Nesiritide (Drug): The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.

+Outcome measures

Primary outcomes

Changes of cardiac output [Before and 30-min after using a standard dose of Nesiritide]: Changes of cardiac output measured by hemodynamical monitoring tools
Changes of systemic filling pressure [Before and 30-min after using a standard dose of Nesiritide]: Changes of the intercept of regression line of paired VR-RAP points at different PEEP levels.

Secondary outcomes

Changes of cardiac function curve [Before and 30-min after using a standard dose of Nesiritide]: Using body position changes (±15°) to simulate the change of preload, and therefore depicte the Starling curve
Changes of venous return curve [Before and 30-min after using a standard dose of Nesiritide]: Changes of venous return curve depicted by different PEEP setting

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age≥18 years；
* Congestive Heart Failure;
* With mechanical ventilation；
* With hemodynamic monitoring devices;
* The physicians made the decision of using Nesiritide.

Exclusion Criteria:

* Unstable hemodynamic status；
* Severe renal dysfunction.

+Locations (1)

Facility	City	Country	Status
Zhongshan Hospital	Xuhui, Shanghai Municipality	China	Recruiting